Anthim market grows on biodefense demand and anthrax risk

The market for obiltoxaximab, sold as Anthim, is expanding as governments increase biodefense spending and health systems prepare for anthrax outbreaks. North America led the market in 2025, while new report features and broader regional coverage point to continued global interest.

Why it matters: - Obiltoxaximab is a targeted treatment for inhalational anthrax, a serious zoonotic threat and potential bioterror response tool. - Demand is tied to biodefense readiness, stockpiling and rapid deployment of medical countermeasures. - Rising outbreaks and higher healthcare spending are increasing attention on anthrax therapies and other emergency treatments.

What happened: - The Business Research Company published its Obiltoxaximab (Anthim) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report covers market conditions, growth drivers, regional trends and the outlook for 2026-2035. - North America was the leading region for the obiltoxaximab market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and key technology and future trend analysis. - The report offers a free sample. - Readers can also view the full market report.

The details: - Obiltoxaximab is a monoclonal antibody that binds to the protective antigen component of anthrax toxin and blocks entry into cells. - The drug is used alongside appropriate antibacterial medicines. - The treatment is approved for adults and children. - Historical market growth was driven by biodefense preparedness, government funding for anthrax countermeasures, approval of monoclonal antibody therapies and emergency medical response protocols. - Future growth is expected to come from larger biodefense stockpiles, more investment in next-generation antitoxin treatments, stronger cross-border health security cooperation and faster deployment of countermeasures. - Advances in monoclonal antibody manufacturing, strategic stockpiling and improved cold-chain logistics are shaping the market outlook. - Rising zoonotic disease incidence is another driver, supported by factors including wildlife contact, urban expansion, climate change and global travel. - The World Health Organization reported 684 suspected anthrax cases across nine of Zambia’s ten provinces in December 2023, with four confirmed fatalities and a mortality ratio of 0.6%. - Higher healthcare expenditure is also supporting the market, including OECD countries’ spending of about 9.3% of GDP on healthcare in 2024, according to an estimate published in November 2025. - Biodefense budgets are expanding globally, including a July 2023 report that the FY2024 U.S. budget proposed $400 million in new discretionary funding for pandemic and biodefense preparedness through BARDA/ASPR.

Between the lines: - The market is small and specialized, but it sits at the intersection of public health, national security and emergency preparedness. - Anthrax outbreaks and biodefense planning can move demand even when routine commercial demand is limited. - Report add-ons such as TAM models and company scoring suggest investors and industry players are looking for a clearer view of a niche market with policy-driven demand.

What's next: - Continued growth will depend on national biodefense budgets, stockpile policy and outbreak response planning. - Cross-border health security cooperation may shape procurement and deployment strategies. - More investment in antitoxin research and manufacturing could widen the treatment pipeline and support future demand.

The bottom line: - Anthim’s market is being pulled forward by preparedness spending, anthrax outbreak risk and broader biodefense priorities.